NewsBenzinga据报道,强生表示,Pasritamig 和 JNJ-9401 在前列腺癌 I 期研究中实现 73% 的 PSA 应答,且未出现 3 级或更高级别的治疗相关不良事件,支持门诊给药 据报道,强生表示,Pasritamig 和 JNJ-9401 在前列腺癌 I 期研究中实现 73% 的 PSA 应答,且未出现 3 级或更高级别的治疗相关不良事件,支持门诊给药 Benzinga 2026.11.09 08:10 (GMT+0) Open on Benzinga Other news AI models can be tricked into identifying civilians as military targets by telling them it’s a game Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies McKesson Stock Is a Triple Threat at New All-Time Highs. How to Trade It Here. 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT